ASTELIN Drug Patent Profile

When do Astelin patents expire, and what generic alternatives are available?

Astelin is a drug marketed by Rising and is included in one NDA.

The generic ingredient in ASTELIN is azelastine hydrochloride. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Astelin

A generic version of ASTELIN was approved as azelastine hydrochloride by APOTEX INC on April 30^th, 2009.

Summary for ASTELIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Patent Applications:	1,938
What excipients (inactive ingredients) are in ASTELIN?	ASTELIN excipients list
DailyMed Link:	ASTELIN at DailyMed

Recent Clinical Trials for ASTELIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ClinResearch, GmbH	Phase 1
MEDA Pharma GmbH & Co. KG	Phase 1
Prolytic GmbH	Phase 1

See all ASTELIN clinical trials

Paragraph IV (Patent) Challenges for ASTELIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ASTELIN	Nasal Spray	azelastine hydrochloride	0.125 mg base/spray	020114	1	2005-11-14

US Patents and Regulatory Information for ASTELIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	ASTELIN	azelastine hydrochloride	SPRAY, METERED;NASAL	020114-001	Nov 1, 1996		DISCN	Yes	No

International Patents for ASTELIN

See the table below for patents covering ASTELIN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	84968
Australia	2506388
Australia	613107
Canada	1319322	MEDICAMENTS CONTENANT DE L'AZELASTINE POUR APPLICATION DANS LE NEX OU DANS LES YEUX (AZELASTINE-CONTAINING MEDICAMENTS FOR APPLICATION IN THE NOSE AND/OR EYE)
Germany	3836579
Germany	3877904
Denmark	174928

Supplementary Protection Certificates for ASTELIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0316633	99C0012	Belgium		PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1519731	C300740	Netherlands		PRODUCT NAME: AZELASTINE OF EEN; NAT. REGISTRATION NO/DATE: RVG114215 20141125; FIRST REGISTRATION: 2011/07125-REG 20130215
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215

ASTELIN (azelastine hydrochloride) nasal spray: Market dynamics, competitive landscape, and financial trajectory

Last updated: July 25, 2026

ASTELIN (azelastine hydrochloride) is an intranasal antihistamine used for allergic rhinitis. In the US market, performance is driven by generic availability, seasonal demand, formulary placement versus intranasal corticosteroids and newer antihistamine combinations, and the presence of branded competitors such as Astepro (also azelastine, typically OTC and/or branded generics depending on product) and other nasal antihistamines. Financial trajectory has tracked the broader post-launch pattern for established branded products: gradual share pressure from generics and SKU proliferation, with revenue increasingly sensitive to pricing, pharmacy benefit manager (PBM) contracting, and category-level substitution toward combination intranasal regimens.

How has ASTELIN performed financially since launch, and what revenue drivers matter most?

Featured snippet answer: ASTELIN’s financial trajectory in the US is dominated by generic substitution and pricing erosion, with upside concentrated in controlled formulary access and periods of peak seasonal demand.

Core revenue drivers for intranasal antihistamines

Key commercial variables that determine ASTELIN unit and revenue outcomes:

• Seasonality: allergic rhinitis sales are highest in spring and early fall; quarterly volatility is typical.
• Formulary positioning: PBM tiering versus intranasal corticosteroids (INCS) like fluticasone, mometasone, and budesonide drives repeat prescribing.
• Substitution to “switchable” azelastine brands/SKUs: azelastine nasal formats face share pressure from branded intranasal antihistamine products and from generic azelastine.
• Payor contracting and net price: branded net revenue typically declines faster than list price as contracts tighten.
• Patient preference and dosing practicality: adherence improves with perceived onset and dosing simplicity, supporting script durability when competing products do not displace.

What usually explains branded revenue declines in this category

For long-established intranasal antihistamines, financial trajectory typically reflects:

• Loss of exclusivity and entry of authorized/unauthorized generics in the same molecule class.
• Rising “channel competition” between prescription and OTC access products in the same active ingredient family.
• SKU fragmentation (different strengths, package sizes, delivery devices), which shifts share even if total class demand is stable.

What is the competitive landscape for ASTELIN (azelastine) in allergic rhinitis?

Featured snippet answer: Competition clusters around (1) INCS-first regimens, (2) intranasal antihistamines as monotherapy or add-on, and (3) azelastine-based combo options that can pull patients away from stand-alone azelastine.

Main competitive vectors

1. Intranasal corticosteroids (INCS)

   • Often first-line for persistent symptoms.
   • Strong efficacy data for congestion and inflammation changes prescribing toward INCS-based regimens.

2. Intranasal antihistamines

   • Azelastine-class drugs compete on symptom relief speed and tolerability.
   • Compared with INCS, antihistamines can win in rapid onset perceptions and in mild-to-moderate disease.

3. Combination products

   • When combinations (INCS + antihistamine) are covered, they can displace monotherapy and shift share.

Where ASTELIN sits versus azelastine competitors

ASTELIN’s competitive position is primarily determined by:

• Whether competing azelastine products have stronger access in common formularies.
• OTC versus prescription dynamics for azelastine-containing products.
• Packaging and copay tiers, which can outweigh clinical differences for many patients.

How does generic entry risk affect ASTELIN’s market share and pricing?

Featured snippet answer: Generic entry typically compresses unit price first, then reduces branded net revenue through contracting, switching, and channel rebalancing.

Mechanisms of financial pressure

• PBM preferred generic substitution reduces prescription volume for branded ASTELIN.
• Copay design shifts utilization toward lower-cost alternatives.
• Wholesale and channel inventory adjustments around generic launches can create temporary swings in revenue recognition.

Typical timeline pattern for branded intranasal antihistamines

• Initial launch period: differentiated positioning and higher net pricing.
• Mid-life: increasing competitor density and formulary tightening.
• Post-generic entry: branded revenue stabilizes at lower levels or declines steadily unless protected by differentiated device/SKU or favorable contracts.

What are the key market dynamics by channel: retail pharmacy, mail order, and institutional?

Featured snippet answer: Retail and mail order dominate the allergic rhinitis intranasal antihistamine category; institutional use is smaller and usually less pivotal for annual revenue.

Retail pharmacy and PBM influence

• Most prescribing decisions are mediated by PBM formularies.
• Net revenue is sensitive to:
  • preferred product lists
  • step therapy policies
  • brand vs generic copay spreads

Mail order

• Often emphasizes maintenance products and 90-day supply economics.
• If a molecule gains preferred status, branded share can drop further.

Institutional

• Allergic rhinitis is usually treated in outpatient settings, limiting institutional share contribution.

How do seasonal patterns translate into quarter-to-quarter financial trajectory for ASTELIN?

Featured snippet answer: ASTELIN’s sales generally peak in allergy seasons, creating a predictable seasonal cadence with Q1 to Q2 upswings and autumn bumps.

What to watch in earnings and business reviews

• Seasonality-adjusted demand: whether non-season volume holds steady, indicating sticky physician and patient behavior.
• Competing category performance: if INCS utilization rises during the same periods, azelastine growth can still stall.
• Net pricing changes: margin compression can occur even when units rise.

How does ASTELIN compare with Astepro (azelastine) on market access and financial resilience?

Featured snippet answer: Both share the azelastine active ingredient; the market outcome usually depends on access, perceived product differentiation, channel mix, and copay coverage rather than molecule-level efficacy alone.

Comparison dimensions that drive financial divergence

• Formulary access: preferred vs non-preferred placement.
• OTC penetration: OTC presence can shift demand away from prescription channels.
• SKU count and pack economics: larger packs reduce effective per-dose cost, affecting adherence and switching.

What patent and exclusivity status drives ASTELIN’s current market dynamics?

Featured snippet answer: For established intranasal azelastine products, market structure is shaped by generic availability and residual patent/formulation protection rather than broad ongoing composition exclusivity.

How to interpret “IP-driven” versus “access-driven” outcomes

• When molecule-level composition exclusivity has expired, current market dynamics become access-driven:
  • PBM contracting
  • OTC vs RX channel
  • clinical guideline adherence patterns
• Remaining IP often influences:
  • device or formulation-specific exclusivity
  • method-of-use claims
  • incremental improvements that can support branded differentiation

(Note: A full patent-by-patent map requires Orange Book listing and jurisdictional details not provided in the prompt.)

What is the Orange Book status of ASTELIN and which patents block generic entry?

Featured snippet answer: The actionable determination is whether the specific ASTELIN NDA is listed in the FDA Orange Book with unexpired patents and whether any are blocking via current listed expiration dates. No Orange Book listing data was provided here, so a definitive patent expiration table cannot be produced.

What generic entry risks exist for ASTELIN, and how do they impact expected revenues?

Featured snippet answer: The primary generic entry risk is already realized for the molecule class in many markets; remaining risks tend to be SKU- or formulation-specific, not composition-level.

Risk pathways that matter commercially

• Switching at the pharmacy counter once a product becomes preferred.
• Manufacturing and supply availability for authorized generics or new entrants affecting market supply balance.
• Brand-to-generic conversion tied to plan formularies which can abruptly alter net revenue.

How do pricing and margin trends typically evolve for legacy intranasal brands like ASTELIN?

Featured snippet answer: Net prices trend downward as generic competition tightens; margins usually compress faster than revenue unless cost reductions and favorable rebates offset.

Net revenue components

• List price declines or stays stable but is not the revenue driver.
• Rebates and chargebacks can increase as contracts are renegotiated.
• Mix shift toward lower-priced channels reduces blended net price.

What manufacturing and supply considerations can affect ASTELIN financial trajectory?

Featured snippet answer: Supply stability and device performance affect adherence and refill continuity; disruptions generally hit units first, then pricing and contracting leverage.

Operational factors that influence commercial results

• device reliability and user technique (nasal sprays)
• packaging format constraints for distribution
• production scale for peak season demand

Key takeaways

• ASTELIN’s market dynamics are primarily driven by PBM access and generic substitution, not by ongoing molecule differentiation.
• Financial trajectory is seasonal, with allergic rhinitis demand producing predictable quarter patterns.
• Competitive pressure comes from intranasal corticosteroids, azelastine-based alternatives, and combination regimens when covered.
• Net revenue is most sensitive to contracting, copay design, and SKU-based switching, which typically compress branded pricing over time.
• IP effects are usually residual and formulation/device-specific for established azelastine products, with access becoming the dominant driver.

FAQs

1. Is ASTELIN still a profitable brand versus generics in allergic rhinitis?
2. How do PBM formularies typically tier intranasal antihistamines like azelastine versus INCS?
3. Do OTC azelastine products cannibalize ASTELIN prescription volume, and how quickly?
4. What combination therapies most often displace stand-alone azelastine sprays in payer coverage?
5. What supply disruptions in nasal spray manufacturing most directly impact seasonal revenue peaks?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. FDA. Drug Approval and Databases (NDA review and labeling lookups). (Accessed via FDA database).
3. FDA. Prescribing Information for ASTELIN (azelastine hydrochloride) nasal spray. (Accessed via FDA labeling database).

DrugChatter Q&A for ASTELIN

Generic for astelin nasal spray?